RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)
University of California, Irvine
Summary
This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Female and male patients diagnosed with cancer and planned to receive an anthracycline- or platinum- containing chemotherapy regimen. * ≥18 years of age. * Life expectancy \> 6 months * Able to provide informed consent. * Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the q…
Interventions
- DrugRiluzole
Given PO
- OtherPlacebo
Given PO
Location
- Chao Family Comprehensive Cancer Center, University of California IrvineOrange, California